Rasch Morten G, Lund Ida K, Almasi Charlotte E, Hoyer-Hansen Gunilla
Finsen Laboratory, Rigshospitalet section 3735, Copenhagen Biocenter, Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark.
Front Biosci. 2008 May 1;13:6752-62. doi: 10.2741/3186.
The cellular receptor for urokinase, uPAR, localizes its ligand, uPA, and thereby the plasminogen activation, to the cell surface. uPA also cleaves uPAR, liberating the ligand-binding domain I, and thereby inactivates the binding potential of uPAR for both uPA and vitronectin. The uPA-catalyzed cleavage of uPAR is fast on the cell surface, when uPA is bound to a neighboring uPAR molecule. uPAR can be shed from the cell surface. However, the soluble form cannot be cleaved by uPA. Glycolipid-anchored and soluble forms of intact, uPAR(I-III), and cleaved receptor, uPAR(II-III) and uPAR(I), have been identified in tissue and body fluids. It is well-established, that the total amount of all uPAR forms is a strong prognostic marker in different types of cancer. Using immunoassays, measuring the individual uPAR forms, has revealed that the cleaved uPAR forms are even stronger prognostic markers and have diagnostic utility. This review will focus on the mechanism of uPAR cleavage and the functional consequences, as well as the clinical applicability of cleaved uPAR forms.
尿激酶的细胞受体uPAR将其配体uPA以及纤溶酶原激活定位到细胞表面。uPA还能切割uPAR,释放出配体结合结构域I,从而使uPAR对uPA和玻连蛋白的结合潜能失活。当uPA与相邻的uPAR分子结合时,uPA催化的uPAR切割在细胞表面进行得很快。uPAR可以从细胞表面脱落。然而,可溶性形式不能被uPA切割。在组织和体液中已鉴定出完整的糖脂锚定和可溶性形式的uPAR(I-III),以及切割后的受体uPAR(II-III)和uPAR(I)。众所周知,所有uPAR形式的总量是不同类型癌症的一个重要预后标志物。使用免疫测定法测量个体uPAR形式发现,切割后的uPAR形式是更强的预后标志物,具有诊断价值。本综述将聚焦于uPAR切割的机制、功能后果以及切割后的uPAR形式的临床应用。